Ipsen to acquire U.S.-based Epizyme for $247 million. By: MarketWatch June 27, 2022 at 02:12 AM EDT The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020 Read More >> Related Stocks: Epizyme Inc Royalty Pharma Plc Cl A
